tbuckley/cabot-search huggingface dataset:
Metabolic remodelling in diabetic cardiomyopathy
Authors: Cher-Rin Chong, Kieran Clarke, Eylem Levelt
Journal: Cardiovascular Research (2017)

Diabetes is a risk factor for heart failure and cardiovascular mortality with specific changes to myocardial metabolism, energetics, structure, and function. The gradual impairment of insulin production and signalling in diabetes is associated with elevated plasma fatty acids and increased myocardial free fatty acid uptake and activation of the transcription factor PPARα. The increased free fatty acid uptake results in accumulation of toxic metabolites, such as ceramide and diacylglycerol, activation of protein kinase C, and elevation of uncoupling protein-3. Insulin signalling and glucose uptake/oxidation become further impaired, and mitochondrial function and ATP production become compromised. Increased oxidative stress also impairs mitochondrial function and disrupts metabolic pathways. The diabetic heart relies on free fatty acids (FFA) as the major substrate for oxidative phosphorylation and is unable to increase glucose oxidation during ischaemia or hypoxia, thereby increasing myocardial injury, especially in ageing female diabetic animals. Pharmacological activation of PPARγ in adipose tissue may lower plasma FFA and improve recovery from myocardial ischaemic injury in diabetes. Not only is the diabetic heart energetically-impaired, it also has early diastolic dysfunction and concentric remodelling. The contractile function of the diabetic myocardium negatively correlates with epicardial adipose tissue, which secretes proinflammatory cytokines, resulting in interstitial fibrosis. Novel pharmacological strategies targeting oxidative stress seem promising in preventing progression of diabetic cardiomyopathy, although clinical evidence is lacking. Metabolic agents that lower plasma FFA or glucose, including PPARγ agonism and SGLT2 inhibition, may therefore be promising options.
Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.
Authors: Elizabeth A. Richey, Charles L. Bennett, Hau C. Kwaan, Anaadriana Zakarija, Nicholas Banderanko, Dilip K. Pandey, June M. McKoy, Paul R. Yarnold, Dennis W. Raisch, Jeffrey L. Winters, Thomas J. Raife, John F. Cursio, Matthew J. Fisher, Thomas L. Ortel, Martin S. Tallman, Masanori Matsumoto, Yoshihiro Fujimura, Joel L. Moake
Journal: Blood (2007)
Umbilical Cord Blood T Cells Express the Natural Cytotoxicity Receptors, NKp30, NKp44 and NKp46 after IL-15 Stimulation, but Only NKp30 Is Functional.
Authors: Qin Tang, Bartosz Grzywacz, Hongbo Wang, Nandini Kataria, John E. Wagner, Bruce R. Blazar, Jeffrey S. Miller, Michael R. Verneris
Journal: Blood (2007)
Treatment of Poor Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia with a Combination of 5-Azacytidine and Valproic Acid
Authors: Andrea Kuendgen, Gesine Bug, Oliver G. Ottmann, Detlef Haase, Barbara Hildebrandt, Kerstin Habersang, Ariane Dienst, Rainer Haas, Ulrich Germing, Norbert Gattermann
Journal: Blood (2008)
Actomyosin contractility drives bile regurgitation as an early response during obstructive cholestasis
Authors: Kapish Gupta, Qiushi Li, Jun Jun Fan, Eliza Li Shan Fong, Ziwei Song, Shupei Mo, Haoyu Tang, Inn Chuan Ng, Chan Way Ng, Pornteera Pawijit, Shuangmu Zhuo, Chen-Yuan Dong, Boon Chuan Low, Aileen Wee, Yock Young Dan, Pakorn Kanchanawong, Peter So, Virgile Viasnoff, Hanry Yu
Journal: Journal of Hepatology (2017)
Erratum to: Ceftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock
Authors: Marc O. Maybauer, Dirk M. Maybauer, John F. Fraser, Lillian D. Traber, Martin Westphal, Robert A. Cox, Ruksana Huda, Yoshimitsu Y. Nakano, Perenlei Enkhbaatar, Hal K. Hawkins, David N. Herndon, Daniel L. Traber
Journal: Intensive Care Medicine (2007)
Does post-induction chemotherapy PET/CT response predict outcome in young adult nasopharyngeal carcinoma? Prospective study from CCHE
Authors: S.A. Ahmed, M. Amr Abdelwahab, E. A.el-Kholy, A. Kamel, S. A.fadel, H. Taha, I. Zaky, A. Elnashar
Journal: Annals of Oncology (2016)
Impact of 21-gene RT-PCR assay on adjuvant therapy for stage I breast cancer.
Authors: Fanny Le Du, Richard L. Theriault, Jie S. Willey, Vicente Valero, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo, Naoto T. Ueno
Journal: Journal of Clinical Oncology (2014)

586 Background: A recurrence score (RS) derived from a 21-gene RT-PCR assay (Oncotype DX) stratifies patients (pts) with early estrogen receptor (ER)-positive, HER2-normal breast cancer (BC) into 3 groups based on risk of 10-year distant metastasis rate: low, intermediate, and high. High RS predicts benefit from chemotherapy follow-by hormonal therapy (CH-T); whether intermediate RS predicts benefit from CH-T is unknown. For Stage I, NCCN Clinical Practice Guidelines recommend use of RS for T1b BC with unfavorable features (angiolymphatic invasion, high histologic or nuclear grade) and T1c BC. However, data are limited on how RS influences treatment of stage I BC. We sought to define the impact of RS on treatment in pts with stage I BC. Methods: In 1057 pts with ER-positive, HER2-normal stage I BC with RS available, we assessed the interaction between RS and treatment by tumor category. Kaplan-Meier survival curves and log-rank tests were used to compare outcomes. Results: Pts with T1a, T1b, and T1c BC did not differ in the distribution of low, intermediate and high RS (P=0.53) (Table). In the T1b and T1c groups, 57% and 52%, respectively, of pts with intermediate RS did not receive chemotherapy. Median follow-up is 25.7 months. Among T1b pts with intermediate RS, disease-free survival did not differ between pts who received HT and those who received CH-T (P=0.84). Among T1b pts with intermediate RS, pts who received CH-T had higher RS than pts who received HT (median 23 vs 21, P<0.001). Conclusions: Less than 10% of patients with stage I had high RS.More than half of pts with stage I BC and intermediate RS received HT alone. Pts with higher RS were more likely to receive CH-T. Among pts with T1b BC and intermediate RS, pts who received HT alone had the similar DFS as those who received CH-T. RS category and treatment No. (%) of pts*** T1a (n=36) T1b (n=296) T1c (n=725) Low 22 173* 391* HT 22 (100) 156 (90) 345 (88) CH-T 0 7 (4) 31 (8) Intermediate 13* 98* 269** HT 11 (85) 56 (57) 140 (52) CH-T 1 (8) 37 (38) 116 (43) High 1 25* 65** HT 0 2 (8) 10 (15) CH-T 1 (100) 21 (84) 52 (80) * DFS did not differ between HT and CH-T (P>0.05). ** DFS differed between HT and CH-T (P<0.05). *** Percentages in some groups total less than 100% because 18 pts received no treatment and 29 pts had missing treatment data.
Rhinovirus Infection Induces Dual Amplification of Virus- and Allergen-Specific T Cells with Discrete Phenotypes in Allergic Asthmatics
Authors: Lyndsey M. Muehling, Peter W. Heymann, Paul W. Wright, Cara E. Wogsland, Jonathan M. Irish, William W. Kwok, Judith A. Woodfolk
Journal: Journal of Allergy and Clinical Immunology (2017)
GATA and BCLxl Downregulation in Erythropoiesis during In Vitro Lineage Specific Differentiation of MDS Hematopoietic Progenitor Cells Is Not Induced by Activated Notch Pathway.
Authors: Olaf J. Hopfer, Martina Komor, Ina S.N. Koehler, Claudia Freitag, Dieter Hoelzer, Eckhard Thiel, Wolf-Karsten Hofmann
Journal: Blood (2007)
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
Authors: Stefan N. Symeonides, Stephen M. Anderton, Alan Serrels
Journal: Journal for ImmunoTherapy of Cancer (2017)

Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy.
Stevens-Johnson Syndrome—A Look Back
Authors: Shields W. Callahan, Vikash S. Oza
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States
Authors: Si-Tien Wang, Hui Huang, Abbie Ba-Mancini, Hongliang Shi, Kristina Chen, Caroline Korves, Ravinder Dhawan, Andrew Cakana, Helgi van de Velde, Dixie-Lee W. Esseltine, Mei S. Duh
Journal: Blood (2010)
Molecular Complete Remission of Clonal Hematopoiesis in Paroxysmal Nocturnal Hemoglobinuria (PNH) after Syngeneic Transplantation.
Authors: Debra Frei-Lahr, Norimitsu Inoue, Carl Wittwer, Mark Herrmann, William Babcock, Taroh Kinoshita, Charles J. Parker
Journal: Blood (2006)
A Population-Based Study In Acute Promyelocytic Leukemia (APL) Suggests a Higher Early Death Rate and Lower Overall Survival Than Commonly Reported In Clinical Trials: Data From the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer Registry In the United States Between 1992–2007
Authors: Jae H. Park, Katherine S Panageas, Maria J Schymura, Baozhen Qiao, Joseph G Jurcic, Todd L. Rosenblat, Jessica K Altman, Dan Douer, Jacob M. Rowe, Martin S. Tallman
Journal: Blood (2010)
Midgut-Derived Activin Regulates Glucagon-like Action in the Fat Body and Glycemic Control
Authors: Wei Song, Daojun Cheng, Shangyu Hong, Benoit Sappe, Yanhui Hu, Neil Wei, Changqi Zhu, Michael B. O’Connor, Pavlos Pissios, Norbert Perrimon
Journal: Cell Metabolism (2017)
Downregulating Notch Signaling in KrasG12D/+ Mice Inhibits Both T-Cell Leukemia and Myeloproliferative Neoplasm in a Cell-Autonomous Manner
Authors: Guangyao Kong, Yuan-I Chang, Erik A. Ranheim, Yun Zhou, Yangang Liu, Paul Lambert, Lan Zhou, Pamela Stanley, Warren S. Pear, Jing Zhang
Journal: Blood (2014)
Mechanically Enhanced Hierarchically Porous Scaffold Composed of Mesoporous Silica for Host Immune Cell Recruitment
Authors: Youngjin Choi, Ji Hoon Jeong, Jaeyun Kim
Journal: Advanced Healthcare Materials (2017)

Hierarchically porous materials have been of interest in many diverse fields, including catalysis, separations, and tissue engineering, because the hierarchical porosity of the materials contributes to improvements in mechanical properties, transport properties, and molecule selectivity. In this study, we, for the first time, introduce a new approach to fabricate hierarchical macroporous and mesoporous silica scaffolds based on a salt-leaching process using as-prepared mesoporous silica as a building block. The mechanical strength of the resulting inorganic 3D scaffold was significantly improved by controlling the interfaces of mesoporous silica particles, which allowed for high structural stability during in vivo implantation. Implantation of the scaffold loaded with pro-inflammatory cytokine in mesopores into mice successfully recruited a high number of host immune cells, including dendritic cells, into the macropores, which shows their potential use for immunomodulation.
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
Authors: R. Dienstmann, M.J. Mason, F.A. Sinicrope, A.I. Phipps, S. Tejpar, A. Nesbakken, S.A. Danielsen, A. Sveen, D.D. Buchanan, M. Clendenning, C. Rosty, B. Bot, S.R. Alberts, J. Milburn Jessup, R.A. Lothe, M. Delorenzi, P.A. Newcomb, D. Sargent, J. Guinney
Journal: Annals of Oncology (2017)

TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation.After imputation of missing at random data, a subset of patients accrued in phase 3 trials with adjuvant chemotherapy (n = 3016)-N0147 (NCT00079274) and PETACC3 (NCT00026273)-was aggregated to construct multivariable Cox models for 5-year overall survival that were subsequently validated internally in the remaining clinical trial samples (n = 1499), and also externally in different population cohorts of chemotherapy-treated (n = 949) or -untreated (n = 1080) CC patients, and an additional series without treatment annotation (n = 782).TNM staging, MSI and BRAFV600E mutation status remained independent prognostic factors in multivariable models across clinical trials cohorts and observational studies. Concordance indices increased from 0.61-0.68 in the TNM alone model to 0.63-0.71 in models with added molecular markers, 0.65-0.73 with clinicopathological features and 0.66-0.74 with all covariates. In validation cohorts with complete annotation, the integrated time-dependent AUC rose from 0.64 for the TNM alone model to 0.67 for models that included clinicopathological features, with or without molecular markers. In patient cohorts that received adjuvant chemotherapy, the relative proportion of variance explained (R2) by TNM, clinicopathological features and molecular markers was on an average 65%, 25% and 10%, respectively.Incorporation of MSI, BRAFV600E and KRAS mutation status to overall survival models with TNM staging improves the ability to precisely prognosticate in stage II and III CC patients, but only modestly increases prediction accuracy in multivariable models that include clinicopathological features, particularly in chemotherapy-treated patients.
39P Impact of GSTP1 and ABCC4 genes polymorphism on outbreak of cyclophosphamide-based chemotherapy-induced grade 3/4 febrile neutropenia in Iranian breast cancer patients
Authors: M. Mobaraki, H. Dehghan Manshadi, A. Faraji, M. Zare, Z. Siavashpour, M.H. Sanati
Journal: Annals of Oncology (2016)
Corrigendum to ‘Diffusion of water-soluble sorptive drugs in HEMA/MAA hydrogels’ [J. Control. Release, 239, (October 10, 2016), 242–248]
Authors: D.E. Liu, T.J. Dursch, N.O. Taylor, S.Y. Chan, D.T. Bregante, C.J. Radke
Journal: Journal of Controlled Release (2017)
In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial
Authors: Julia Hoellenriegel, Susan O'Brien, Michael J. Keating, William G. Wierda, Joseph J. Buggy, Jan A. Burger
Journal: Blood (2012)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up
Authors: Jorge E Cortes, Anish Maru, Carmino Antonio Antonio De Souza, François Guilhot, Ladan Duvillie, Christine Powell, Athena Countouriotis, Carlo Gambacorti-Passerini
Journal: Blood (2011)
Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis
Authors: Caroline Ospelt, Holger Bang, Eugen Feist, Giovanni Camici, Stephan Keller, Jacqueline Detert, Anette Krämer, Steffen Gay, Khetam Ghannam, Gerd R Burmester
Journal: Annals of the Rheumatic Diseases (2017)

Smoking has been connected to citrullination of antigens and formation of anti-citrullinated peptide antibodies (ACPAs) in rheumatoid arthritis (RA). Since smoking can modify proteins by carbamylation (formation of homocitrulline), this study was conducted to investigate these effects on vimentin in animal models and RA.The efficiency of enzymatic carbamylation of vimentin was characterised. B-cell response was investigated after immunisation of rabbits with different vimentin isoforms. Effects of tobacco smoke exposure on carbamylation of vimentin and formation of autoantibodies were analysed in mice. The antibody responses against isoforms of vimentin were characterised with respect to disease duration and smoking status of patients with RA.Enzymatic carbamylation of vimentin was efficiently achieved. Subsequent citrullination of vimentin was not disturbed by homocitrullination. Sera from rabbits immunised with carbamylated vimentin (carbVim), in addition to carbVim also recognised human IgG-Fc showing rheumatoid factor-like reactivity. Smoke-exposed mice contained detectable amounts of carbVim and developed a broad immune response against carbamylated antigens. Although the prevalence of anti-carbamylated antibodies in smokers and non-smokers was similar, the titres of carbamylated antibodies were significantly increased in sera of smoking compared with non-smoking RA. CarbVim antibodies were observed independently of ACPAs in early phases of disease and double-positive patients for anti-mutated citrullinated vimentin (MCV) and anti-carbVim antibodies showed an extended epitope recognition pattern towards MCV.Carbamylation of vimentin is inducible by cigarette smoke exposure. The polyclonal immune response against modified antigens in patients with RA is not exclusively citrulline-specific and carbamylation of antigens could be involved in the pathogenesis of disease.ISRCTN36745608; EudraCT Number: 2006-003146-41.
Use of Plerixafor to Overcome Stem Cell Mobilization Failure: Long Term Follow up of Patients Proceeding to Transplant Using Plerixafor Mobilized Stem Cells
Authors: Abhinav Deol, Judith Abrams, Ashiq Masood, Zaid Al-Kadhimi, Muneer H. Abidi, Lois Ayash, Voravit Ratanatharathorn, Lawrence G Lum, Joseph P. Uberti
Journal: Blood (2011)
Severe asthma: phenotyping to endotyping or vice versa?
Authors: Alberto Papi, Marina Saetta, Leonardo Fabbri
Journal: European Respiratory Journal (2017)

The most recent definition of asthma is that it is a heterogeneous disease, usually characterised by chronic airway inflammation, defined by a history of chronic respiratory symptoms that vary over time, both in frequency and intensity, and associated with variable airflow limitation [1]. Admittedly, asthma is used as an umbrella term, like anaemia, arthritis and cancer. This highlights the importance of taking an individualised approach to a patient's diagnosis and management, using genomics, proteomics, and "humanomics" as emphasised in the GINA guidelines [2]. The vague definition reflects our poor understanding of the underlying mechanisms of the disease, particularly of its more severe expressions. In the guidelines, they are included in steps 4 and 5 of treatment. This might imply that so-called severe asthma is at the extreme of a continuum of severity, something which has never been demonstrated in prospective studies. Molecular rather than clinical phenotyping of airway inflammation might be used in the treatment of severe asthma <http://ow.ly/9Kba308jaXX>
SAFETY of PROTHROMBIN COMPLEX CONCENTRATES IN PATIENTS REQUIRING RAPID REVERSAL of ANTICOAGULANT TREATMENT with the VITAMIN K ANTAGONISTS: a Systematic Review and a Meta-Analysis of the Literature.
Authors: Francesco Dentali, Chiara Marchesi, Matteo Giorgi Pierfranceschi, Mark A. Crowther, David Garcia, Elaine M. Hylek, Dan Witt, Nathan Clark, Alessandro Squizzato, Davide Imberti, Walter Ageno
Journal: Blood (2010)
Multivariate dimensions of hemotologic chaos indices for responders versus non-responders of patients with myelodysplastic syndromes (MDS) after treatment with ptx/cipro/decadron: A qualitative study
Authors: R. R. Huang, A. Raza
Journal: Journal of Clinical Oncology (2007)

17540 Background: In our clinical study of 35 MDS patients who were treated with PTX/Cipro/Decadron, there was an 80% response rate in terms of achieving improved hematopoiesis (responders) during a 4-week period. The primary question of interest was, “What were the hematologic dynamic patterns that transpired between patients who responded versus those who did not?” The purpose of this study was an attempt to answer this question by applying chaos theory to peruse the underlying patterns that may have prognosis utility. Methods: Responders and non-responders were identified and were matched by age, sex, and FAB type. Only those patients who have sufficient and complete hematologic evaluations after treatment with at least 6 months follow-up to derive stable chaotic indices were included. The resulted sample was 3 patients from the non-responded group and 4 patients from the responded group. The three selected hematoloic parametes were white blood count, hemoglobin and platelets. The selected chaos index to indicate its magnitude of across time was the fractal dimension that has three components, namely capacity, information and correlational. Results: The mean ages for the non-responders and responders were 68 and 65, respectively. The median number of weeks evaluated was 38 for the non-responders and 35 weeks for the responders. The three hematologic parameters were analyzed simultaneously in the form of 3-dimensional space. Table indicates the chaos fractal indices for the two groups. Conclusion: Across the three indices, non-responders have an average of 7.4 % larger than responders, suggesting the former exhibited a relatively higher degree of “chaos” than the latter. For prognosis purpose, this result also suggests that patients who exhibit lower magnitude of the chaotic phenomena, will have a higher probability of responding to therapy. This work was done while the authors were at Rush-Presbyterian-St.Luke’s Medical Center. [Table: see text] No significant financial relationships to disclose.
Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies
Authors: Richard L. Wasserman, Sudhir Gupta, Mark R. Stein, Isaac Reuven Melamed, Jennifer M. Puck, Werner Engl, Heinz Leibl, Christopher J. Rabbat, Leman Yel
Journal: Journal of Allergy and Clinical Immunology (2017)
Initial Liver Involvement in Acute Graft-Versus-Host Disease (GVHD) Predicts a Severe Acute Gvhd and Poor Long-Term Survival
Authors: Marie Robin, Raphael Porcher, Renato de Castro, Gustavo Fisher, Regis Peffault de Latour, Patricia Ribaud, Agnes Devergie, Vanderson Rocha, Jean Yves Mary, Gerard Socie
Journal: Blood (2008)